Journal of Thyroid Disorders & Therapy
Open Access
ISSN: 2167-7948
+44 1300 500008
ISSN: 2167-7948
+44 1300 500008
Maleesha Rasanji Jayasinghe
Nanjing Medical University, China
Scientific Tracks Abstracts: Thyroid Disorders Ther
Type 1 diabetes (T1D) is a chronic condition characterized by insufficient insulin production due to the destruction of pancreatic beta cells. T1D can affect both children and adults, and its prevalence is expected to rise in the future. The exact cause of T1D is not known, but it is believed that genetic and environmental factors, along with viral exposure, play a role in its development. Current treatments for T1D involve the use of exogenous insulin, islet cell transplantation, and pancreatic transplantation. However, these treatments have limitations such as the need for immunosuppressants, limited availability of donor islets, and invasive surgery. Mesenchymal stem cells (MSCs) have emerged as a promising treatment option for T1D. However, there are challenges associated with MSCs. This article primarily focuses on the role of MSCs in treating T1D and compares their feasibility, benefits, and drawbacks.
Maleesha Rasanji Jayasinghe, 6th-year medical student at Nanjing Medical University.